Since the last CCSG renewal, Development Funds have supported 1) the recruitment of nine outstanding young investigators, 2) development of three new shared resources and a new service in an existing shared resource, and 3) partial funding for eight MD Anderson Multidisciplinary Research Program (MRP) awards, and three MD Anderson/Baylor Collaborative Multidisciplinary Research Projects. Some $435,000 of CCSG support for faculty recruitment has leveraged $4.5M in MD Anderson start-up packages and more than $11.6M in new extramural grants. MRP awards provide seed funding of $250,000 over 3 years for groups of three or more center members to support planning and development of cores and projects, and to obtain preliminary data for submission of an application for a P01, SPORE or CPRIT multi-investigator grant. Since the inception of MRP awards in 1997, MD Anderson has invested $7.6 million in these seed grants, associated with external peer-reviewed funding of more than $121 million, a 16-fold return on investment Since the last renewal, 8 proposals supported with $535,955 from CCSG Development Funds and matched approximately 2:1 with institutional funds, have leveraged $7,433,633 in peer-reviewed funding. Three Baylor/MD Anderson Collaborative MRPs supported with $92,518 in CCSG Development Funds resulted in a P01 award in 2011 of more than $13M over 5 years to Drs. E. Shall (MD Anderson) and C Bollard (Baylor) for their studies on improving cord blood transplantation in patients with cancer. Development funds supported establishing the Translational and Analytical Chemistry Core, the Characterized Cell Line Core, and the Functional Proteomics Reverse Phase Protein Array Core, which in aggregate have provided services to 273 center members and resulted in more than 200 publications. The Mutant Mouse Pathology Service has become part of the Research Animal Support Facility. In the current CCSG application. Development funds are requested to continue support for faculty recruitment and fund additional MRP awards. Support is also requested for three developing shared resources: the shRNA and Open Reading Frame Core, the High Throughput TALEN Engineering Core, and eHealth Technology. A competitive internal peer-review mechanism is also proposed for the allocation of Development Funds to provide support for establishing new methods and implementing new technologies within the shared resources.

Public Health Relevance

The budgetary flexibility afforded by the use of Development Funds facilitates strengthening of the cancer center through recruitment of outstanding new members, enables new technologies and shared resource services to be established, and enhances the competitiveness of applications for multi-investigator awards.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-39
Application #
8759809
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
39
Fiscal Year
2014
Total Cost
$935,374
Indirect Cost
$351,010
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Abaza, Yasmin; M Kantarjian, Hagop; Faderl, Stefan et al. (2018) Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol 93:91-99
Ok, Chi Young; Loghavi, Sanam; Sui, Dawen et al. (2018) Persistent IDH1/2 mutation in remission can predict relapse in patients with acute myeloid leukemia. Haematologica :
Ajani, Jaffer A; Estrella, Jeannelyn S; Chen, Qiongrong et al. (2018) Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors. Br J Cancer 118:52-61
Gharpure, Kshipra M; Pradeep, Sunila; Sans, Marta et al. (2018) FABP4 as a key determinant of metastatic potential of ovarian cancer. Nat Commun 9:2923
Khan, Maliha; Muzzafar, Tariq; Kantarjian, Hagop et al. (2018) Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. Ann Hematol 97:1183-1191
Somaiah, Neeta; Beird, Hannah C; Barbo, Andrea et al. (2018) Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations. Oncotarget 9:19891-19899
Sandulache, Vlad C; Michikawa, Chieko; Kataria, Pranav et al. (2018) High-Risk TP53 Mutations Are Associated with Extranodal Extension in Oral Cavity Squamous Cell Carcinoma. Clin Cancer Res 24:1727-1733
Puli, Oorvashi Roy; Danysh, Brian P; McBeath, Elena et al. (2018) The Transcription Factor ETV5 Mediates BRAFV600E-Induced Proliferation and TWIST1 Expression in Papillary Thyroid Cancer Cells. Neoplasia 20:1121-1134
Chang, Geraldine H; Kurzrock, Razelle; Tran, Lisa et al. (2018) TP53 mutations and number of alterations correlate with maximum standardized uptake value (SUVmax) determined by positron emission tomography/computed tomography (PET/CT) [18F] fluorodeoxyglucose (18F-FDG PET). Oncotarget 9:14306-14310
Abaza, Yasmin; Cortes, Jorge; Ravandi, Farhad et al. (2018) Prognostic significance of hyperdiploidy in adult acute myeloid leukemia. Am J Hematol 93:E357-E360

Showing the most recent 10 out of 12418 publications